MedServ. GmbH   Report issue

For profit Phase 2
Founded: Leipzig Germany (1992)
Status: No NME R&D (1992)

Organization Overview

First Clinical Trial
2003
NCT00189410
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2003

Timeline

NOW
  • Now

Active Ingredients

Drugs in Phase 2 Trials (2)

carboplatin (paraplatin) (1 trial)

doxorubicin (Doxil) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Genital Neoplasms, Female (Phase 2)

Neoplasms (Phase 2)

Ovarian Neoplasms (Phase 2)

Uterine Neoplasms (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 1
  • # of Trial APIs: 2